abstract |
Enantiomerically pure (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydroisoindol-2-yl)-propionamide, and pharmaceutically acceptable salt or solvate thereof are disclosed. These compounds are suitable for treating and/or preventing various diseases and disorders, such as those ameliorated by the reduction of levels of TNF-alpha or the inhibition of PDE4, and are particularly suitable for treating cancer. |